Edgewise Therapeutics, a pharmaceutical company in the USA, specializes in developing innovative treatments for rare muscle disorders. With a medium risk rating score of 28.5, the company is dedicated to creating orally bioavailable, small molecule therapies for musculoskeletal diseases. Discover cutting-edge ESG-focused solutions for severe health challenges with Edgewise Therapeutics.